Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
Rigel will present final Phase 3 data for GAVRETO (pralsetinib) in RET fusion-positive NSCLC at the ASCO Annual Meeting, where the drug met its primary PFS endpoint and showed superior response rates versus standard of care. The company also highlighted real-world data for REZLIDHIA (olutasidenib) in relapsed/refractory AML, showing a 60.8% CR/CRh rate and median response duration of 30.3 months in patients previously treated with venetoclax.
Key figures
- Drug Name
- GAVRETO (pralsetinib), REZLIDHIA (olutasidenib)
- Phase Of Trial
- Phase 3 (AcceleRET-Lung), Phase 1/2 (ARROW)
- Rezlidhia 48mo os
- 74%
- Rezlidhia lt cr rate
- 50%
- Gavreto infection rate
- 72%
- Gavreto pfs endpoint met
- Yes
- Gavreto fatal infection rate
- 7%
- Rezlidhia real world cr rate
- 60.8%
- Rezlidhia real world crh rate
- 57%
- Rezlidhia median response duration
- 30.3 months
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.